Mode
Text Size
Log in / Sign up

High prevalence and multidrug resistance of gram-negative bloodstream infections in children with acute myeloid leukemia

High prevalence and multidrug resistance of gram-negative bloodstream infections in children with ac…
Photo by National Institute of Allergy and Infectious Diseases / Unsplash
Key Takeaway
Note 27.4% gram-negative infection prevalence in pediatric AML induction; observational design limits causal inference.

This retrospective cohort study analyzed data from 90 children with acute myeloid leukemia admitted for induction chemotherapy at Children’s Cancer Hospital Egypt 57357. The investigation focused on the prevalence and antibiotic susceptibility patterns of gram-negative bloodstream infections during a 30-day follow-up period. No comparator group was reported for this observational analysis.

The study found that 27.4% of 90 children experienced at least one gram-negative bloodstream infection. Among these infections, 80% were identified as multi-drug resistant gram-negative bloodstream infections, representing 72/90 children. Cumulative infection-related mortality was reported at 27.8%, with a confidence interval of 18.9-37.3%. Specific pathogen prevalence included E. coli at 54.8%, K. pneumoniae at 16.9%, A. baumannii at 6.5%, E. cloacae at 4.8%, and P. aeruginosa at 4.0%.

Significant morbidity was associated with these infections. Typhlitis occurred in 32.2% of the cohort, equating to 29/90 children. Admission to intensive care unit was required for 42% of patients, or 38/90 children. Sepsis-related central venous catheter removal was documented in 13.3% of cases, corresponding to 12/90 children. Serious adverse events included infection-related mortality.

The certainty of this evidence is limited by the retrospective analysis design. The authors note an association between gram-negative bacteremia and morbidity/mortality rather than causality. Practice relevance suggests a need for keen surveillance globally of the epidemiology of multi-drug resistant gram-negative organisms and thoughtful studies into antibiotic stewardship.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundIn children receiving therapy for acute myeloid leukemia (AML), gram-negative bacteremia is associated with significant morbidity and mortality, especially in the presence of multi-drug resistant [MDR] organisms. objectives: The purpose of this study was to determine the prevalence and antibiotic susceptibility patterns of gram negativebloodstream infections [GNBSI]] during the period of induction chemotherapy [IC] and the associated morbidity and mortality in a large pediatric oncology hospital in a low- middle-income country (LMIC). patients and methods: This is a retrospective analysis of consecutive newly diagnosed patients with acute myeloid leukemia (AML) admitted for induction chemotherapy (IC) from January 2015 to December 2017 at the Children’s Cancer Hospital Egypt 57357.ResultsWe identified 90[27.4%] children with at least one GNBSI during induction, 72/90[80%] of whom had at least one MDR GNBSI. 124 GNBSI episodes were identified among the ninety children: E.coli 54.8%, K.pneumoniae 16.9%, A.baumannii 6.5%, E.cloacae 4.8%, and P.aeruginosa 4.0%. Thirty-day cumulative infection-related mortality was 27.8% [18.9-37.3%]. Associated morbidity included typhlitis [29/90 (32.2%)], sepsis-related central venous catheter [CVC] removal [12/90 (13.3%)], and admission to intensive care unit [38/90(42%)]. ConclusionOur study highlights the prevalence of gram-negative bacteria among febrile neutropenic children with AML and the high incidence of antibiotic resistance in our hospital. There is a need for keen surveillance globally of the epidemiology of multi-drug resistant gram-negative organisms and thoughtful studies into antibiotic stewardship to reduce the growing threat of MDR GN infections and the associated morbidity and mortality.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.